[ad_1]
Florida Celebration, March 25, 2024 (GLOBE NEWSWIRE) — Zevra Therapeutics, Inc. (NASDAQ: ZVRA) (Zevra or Company), a rare disease therapeutics company, today announced that it will participate in the upcoming 23RD The annual Needham Virtual Healthcare Conference will be held virtually on April 8-9, 2024. The company’s presentation will be held on Monday, April 8, 2024 at 3:45 pm ET. In addition, members of the Zevra management team will participate in one-on-one investor meetings with registered attendees throughout the conference.
The webcast will be held here. After the Zevra presentation, you can access the archived presentation under “Events & Presentations” in the Investor Relations section of the Zevra website at Investors.zevra.com. To register for the conference, please contact your Needham sales representative.
About Zevra Therapy:
Zevra Therapeutics is a rare disease company that combines science, data and patient need to create transformative therapies for diseases with limited or no treatment options. Our mission is to bring life-changing treatments to patients with rare diseases. With a unique, data-driven development and commercialization strategy, the company is overcoming complex drug development challenges to deliver novel therapies to the rare disease space.
For more information, visit www.zevra.com or follow us on X (formerly Twitter) and LinkedIn.
Cautionary Note Regarding Forward-Looking Statements:
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that relate solely to historical or current facts, including, without limitation, statements regarding upcoming events or Zevra’s involvement in such events. Forward-looking statements are based on information currently available to Zevra and its current plans or expectations. They are subject to a number of known and unknown uncertainties, risks and other important factors that may cause any difference between our actual results, performance or achievements and any future results, performance or achievements expressed or implied by the forward-looking statements. Significant difference. These and other important factors are described in detail in the “Risk Factors” section of Zevra’s Annual Report on Form 10-K for the year ended December 31, 2022, and in Zevra’s Quarterly Report on Form 10-Q for the quarter ended September Updated as of December 30, 2023, and other filings by Zevra with the Securities and Exchange Commission. Although we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. Although we believe that the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
Zefra contact information:
Nicole Ochsner
+1 (732) 754-2545
nochsner@zevra.com
Russell partner contact details:
David Schur
+1 (858) 717-2310
david.schull@russopartnersllc.com
Dr. Ignacio Guerrero-Ross
+1 (646) 942-5604
ignacio.guerrero-ros@russopartnersllc.com
[ad_2]
Source link